Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended ...

Switzerland-based FKG Dentaire, a leader in dental equipment manufacturing, has expanded its market presence to the UK. This move is poised to bring advanced dental solutions to British dental ...

H. Lundbeck A/S (Lundbeck) announced that Vyepti® (eptinezumab) met the primary and all key secondary endpoints in SUNRISE, a phase III pivotal clinical trial predominantly conducted in Asia ...

Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo ...

David Finch, Assistant Director of Healthy Lives at the Health Foundation, commenting on National life tables – life expectancy in England and Wales: 2021 to 2023, said, “Today’s ONS release shows a ...

The Agriculture and Horticulture Development Board has issued a vital alert to UK cattle farmers regarding a growing risk of lungworm infections. Due to prevailing weather conditions, the potential ...

Shimadzu Corporation has invested in Rhinoflux Inc., a company pioneering carbon dioxide capture and biomass energy technologies, through its Shimadzu Future Innovation Fund (FIF). This investment ...

Dental support organisation Benevis is revolutionising patient care by implementing an assisted hygiene delivery model. Designed to improve both efficiency and patient experience, this model aims to ...

Responding to the Care Quality Commission’s State of Care report 2023/24, Director of Policy at the Health Foundation, Hugh Alderwick, said: “Following Lord Darzi’s stark diagnosis of the state of the ...

bioAffinity Technologies, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...

In a strategic financial move, Acadia Pharmaceuticals has successfully sold a pediatric review voucher (PRV) for $150 million, resulting in a substantial $100 million profit. This transaction ...